Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allodepleted haploidentical T cells expressing inducible Caspase 9

Allodepleted haploidentical T-lymphocytes transduced with the Gal-V pseudotyped retrovirus vector encoding SFG.iCasp9-2A-deltaCD19, with potential immune reconstitution property. SFG.iCasp9-2A-deltaCD19 contains the suicide gene inducible caspase 9 (iCasp9) linked with a 2A-like cleavable peptide to the selectable marker, truncated human CD19 (deltaCD19). iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9 using a short linker (SGGGS). Donor T cell therapy may help control transplant-related viral infections following allogeneic hematopoietic stem cell transplantation. However, even the addition of allodepleted donor T cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V domain activating caspase 9. This results in the death of T cells causing GVHD while sparing the virus reactive T-cells.
Synonym:iCasp9 allogeneic T cells
Search NCI's Drug Dictionary